UK markets closed

BNTX Jan 2025 155.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.45000.0000 (0.00%)
As of 11:28AM EDT. Market open.
Full screen
Previous close0.4500
Open0.4500
Bid0.1000
Ask0.7000
Strike155.00
Expiry date2025-01-17
Day's range0.4500 - 0.4500
Contract rangeN/A
Volume1
Open interest21
  • Zacks

    Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod

    Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.

  • Globe Newswire

    Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union

    The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical and epidemiological data showing that the JN.1-adapted monovalent COVID-19 vaccine generates an improved immune response against multiple JN.1 sublineagesDoses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission NEW YORK and MAINZ, Germany, June 27, 2024 — P

  • Globe Newswire

    BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer

    Designation is based on pre-clinical data and data from an ongoing Phase 1/2 trial for BNT324/DB-1311, with antitumor activity and a manageable safety profile demonstrated by preliminary Phase 1/2 clinical data from patients with advanced or metastatic solid tumors1,2With the Fast Track designation, the development of BNT324/DB-1311 can benefit from more frequent engagement with the U.S. Food and Drug Administration (“FDA”) to support development and expedite regulatory reviewProstate cancer is